Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers.